The price of this new AD drug will be reduced by 50% from January next year

Alzheimer's disease (AD) refers to a degenerative disease of the central nervous system that occurs in old age and pre-senility and is characterized by progressive cognitive dysfunction and behavioral impairment.
It is clinically manifested as memory impairment and aphasia
.
According to data from the International Alzheimer's Association, more than 50 million people worldwide have dementia in 2019
.
Without intervention, it will increase to 152 million in 2050
.
It should be noted that, unlike the increasing number of patients, in the medical industry, the development of new drugs for Alzheimer’s disease is very Mount Everest, which is difficult to climb, has a very high risk and failure rate; this has also led to the fact that since the discovery of Alzheimer’s disease for more than 100 years, there are still few drugs used for clinical treatment in the world, and they are expensive.
Caused a great burden
.
However, there is good news in the price of AD drugs recently
.
On December 20, Biogen announced that the wholesale purchase price of the new Alzheimer's disease drug Aduhelmd (100mg/ml specification) would be reduced by approximately 50% from January 1, 2022
.
For a patient with an average weight of 74kg, the annual maintenance treatment cost is $28,200
.
It is understood that Bojian’s move is aimed at reducing the out-of-pocket expenses of AD patients using Aduhelmd and reducing the burden on the US medical and health system
.
In addition, the relevant person in charge also pointed out: The US Medical Insurance and Medicaid Services Center is considering including Aduhelmd and other drugs in the coverage, hoping to allow more AD patients to use innovative therapies
.
Biogen expects that 50,000 people will start using Aduhelmd treatment in 2022
.
According to the data, Aduhelm is the first drug of its kind approved by the U.
S.
Food and Drug Administration (FDA) since 2003
.
It is a high-affinity, fully human IgG1 monoclonal antibody targeting the -A β conformational epitope, which can selectively bind to the amyloid deposits in the brains of AD patients, and then activate the immune system to remove the Deposition protein removal
.
The price cut is expected to benefit a large number of patients
.
In fact, for patients with Alzheimer's disease, huge drug costs have always been a heavy burden in treatment
.
At home, the same is true
.
According to surveys, in 2015, China’s Alzheimer’s disease patients spent an average of 130,000 yuan per year, resulting in a total social and economic burden of about 1,140.
6 billion yuan
.
At present, there are about 10 million patients with Alzheimer's disease in China, the number is among the top in the world, and as the aging of the population accelerates, it will further drive the increase in the number of patients.
It is estimated that by 2050, the number of patients with Alzheimer's disease in China will exceed 40 million.
People
.
In order to further alleviate the burden of patients with Alzheimer's disease in China, in addition to accelerating the development of new drugs by pharmaceutical companies and providing patients with more choices, the country is also accelerating the introduction of AD drugs into medical insurance
.
It is understood that on December 3, the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2021)" was officially announced.
The negotiation of 67 kinds of exclusive drugs outside the catalog was successful, and the average price was reduced by 61.
71%
.
Among them, China's original new drug for the treatment of Alzheimer's disease, mannite sodium capsules (trade name: "Nine Phase One") was included in the catalog.
Related news showed that the price of mannite sodium capsules dropped from 895 yuan per box to 296 yuan, a drop of more than 60%
.
With the huge drop, the industry is expected to reduce the burden of treatment for a large number of patients
.